Efektivitas Deferasirox pada Pasien Thalasemia Mayor: Artikel Review

Efficacy of Deferasirox for Thalassemia Mayor: Review Article


  • Naksa Garnida Arfie Universitas Airlangga
  • Bambang Subakti Zulkarnaen Universitas Airlangga, Surabaya, Indonesia
  • Sudarmanto Sudarmanto Rumah Sakit Umum Daerah Dr. Harjono Ponorogo, Indonesia




thalassemia, deferasirox, efficacy


Thalassemia is a heterogeneous grouping of genetic disorders resulting from decreased synthesis of the alpha or beta chains of hemoglobin. Anemia and iron overload are the main causes of morbidity and mortality due to thalassemia disease. Iron chelation has improved the survival and quality of life of patients with thalassemia major. Deferasirox (DFX) was developed as monotherapy for the treatment of transfusion iron overload. Search data in this literature study using an electronic database, namely Science Direct, Pubmed with the keywords thalassemia, deferasirox and efficacy. The search results obtained 1015 articles and 5 articles that matched the inclusion and exclusion criteria. The total patients in this study were 410 people from 5 countries. The results of the review article found that deferasirox was effective in reducing iron in the body as seen from the LIC (Liver Iron Concentration), T2* heart and serum ferritin in patients with thalassemia major.


H. Bajwa and H. Basit, “Thalassemia,” Brenner’s Encycl. Genet. Second Ed., pp. 60–62, Nov. 2021, doi: 10.1016/B978-0-12-374984-0.01534-5.

H. Sawitri and C. A. Husna, “Karakteristik Pasien Thalasemia Mayor Di Blud Rsu Cut Meutia Aceh Utara Tahun 2018,” AVERROUS J. Kedokt. dan Kesehat. Malikussaleh, vol. 4, no. 2, p. 62, 2018, doi: 10.29103/averrous.v4i2.1038.

L. De Franceschi et al., “Oxidative stress and ? -thalassemic erythroid cells behind the molecular defect,” Oxid. Med. Cell. Longev., 2013, doi: 10.1155/2013/985210.

M. A. Yesilipek et al., “A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with ?-Thalassemia Major,” Biol. Blood Marrow Transplant., vol. 24, no. 3, pp. 613–618, Mar. 2018, doi: 10.1016/J.BBMT.2017.11.006.

A. Ansari-Moghaddam, H. A. Adineh, I. Zareban, M. Mohammadi, and M. Maghsoodlu, “The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran,” Epidemiol. Health, vol. 40, p. e2018048, 2018, doi: 10.4178/EPIH.E2018048.

M. J. Cunningham, E. A. Macklin, E. J. Neufeld, and A. R. Cohen, “Complications of ?-thalassemia major in North America,” Blood, vol. 104, no. 1, pp. 34–39, Jul. 2004, doi: 10.1182/BLOOD-2003-09-3167.

M. R. Alipour, Z. Pezeshkpour, S. M. Namayandeh, and M. Sarebanhassanabadi, “Evaluation of ECG and echocardiographic findings in patients aged 2 to 18 years affected with thalassemia major,” Prog. Pediatr. Cardiol., vol. 63, p. 101454, Dec. 2021, doi: 10.1016/J.PPEDCARD.2021.101454.

S. Susanah et al., “Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe ? -Thalassemia,” Biomed Res. Int., vol. 2020, 2020, doi: 10.1155/2020/8185016.

C. Takpradit et al., “Using of deferasirox and deferoxamine in refractory iron overload thalassemia,” Pediatr. Int., vol. 63, no. 4, pp. 404–409, Apr. 2021, doi: 10.1111/PED.14444.

O. E. Orisakwe, C. N. Amadi, and C. Frazzoli, “Management of Iron Overload in Resource Poor Nations: A Systematic Review of Phlebotomy and Natural Chelators,” J. Toxicol., vol. 2020, 2020, doi: 10.1155/2020/4084538.

C. Borgna-Pignatti and M. Marsella, “Iron Chelation in Thalassemia Major,” Clin. Ther., vol. 37, no. 12, pp. 2866–2877, Dec. 2015, doi: 10.1016/J.CLINTHERA.2015.10.001.

Y. Aydinok et al., “Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload,” Blood, vol. 125, no. 25, pp. 3868–3877, Jun. 2015, doi: 10.1182/BLOOD-2014-07-586677.

J. C. Wood et al., “The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores,” Blood, vol. 116, no. 4, pp. 537–543, Jul. 2010, doi: 10.1182/BLOOD-2009-11-250308.

D. J. Pennell et al., “A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with ?-Thalassemia Major and Iron Overload (CORDELIA).,” Blood, vol. 120, no. 21, p. 2124, Nov. 2012, doi: 10.1182/BLOOD.V120.21.2124.2124.

Y.-R. Lai et al., “Efficacy and Safety of Deferasirox in Chinese Patients with Non-Transfusion-Dependent Thalassemia: 1-Year Results from the Thetis Study,” Blood, vol. 126, no. 23, pp. 4570–4570, Dec. 2015, doi: 10.1182/BLOOD.V126.23.4570.4570.

A. T. Taher et al., “Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study,” Blood, vol. 120, no. 5, pp. 970–977, Aug. 2012, doi: 10.1182/BLOOD-2012-02-412692.

A. J. Marengo-Rowe, “The thalassemias and related disorders,” Proc. (Bayl. Univ. Med. Cent)., vol. 20, no. 1, p. 27, Jan. 2007, doi: 10.1080/08998280.2007.11928230.

“IRON OVERLOAD AND CHELATION - Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) - NCBI Bookshelf.” https://www.ncbi.nlm.nih.gov/books/NBK269373/ (accessed Mar. 26, 2022).

H. Dou, Y. Qin, G. Chen, and Y. Zhao, “Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis,” Acta Haematol., vol. 141, no. 1, pp. 32–42, Jan. 2019, doi: 10.1159/000494487.

M. Puliyel et al., “Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload,” Am. J. Hematol., vol. 89, no. 4, pp. 391–394, 2014, doi: 10.1002/AJH.23650.




How to Cite

Arfie, N. G., Zulkarnaen, B. S., & Sudarmanto, S. (2022). Efektivitas Deferasirox pada Pasien Thalasemia Mayor: Artikel Review: Efficacy of Deferasirox for Thalassemia Mayor: Review Article. Jurnal Sains Dan Kesehatan, 4(3), 354–362. https://doi.org/10.25026/jsk.v4i3.1159